Fundraising FoxInflaRx
Jena, DE · 2 known investors
Find your way into InflaRx
Sign up to see every warm intro you have to InflaRx
- Paths you didn't know you had: your email and LinkedIn already hold routes to the InflaRx team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
InflaRx is a biopharmaceutical company developing anti-C5a and anti-C5aR complement inhibitors targeting the complement activation factor C5a and its receptor. Its lead product, GOHIBIC (vilobelimab), received a U.S. FDA Emergency Use Authorization for treating COVID-19 in certain hospitalized adults.
Investors · 2
Funding
SEC filings, press & company announcements$150M disclosed across 1 round · 2026
- $150MraisedMay 2026 · 3 sourcesSource ↗
Source: company announcements and press reports — follow each round's link for the claim.
In the news
Frequently asked questions
- What does InflaRx do?
- InflaRx is a biopharmaceutical company developing anti-C5a and anti-C5aR complement inhibitors targeting the complement activation factor C5a and its receptor. Its lead product, GOHIBIC (vilobelimab), received a U.S. FDA Emergency Use Authorization for treating COVID-19 in certain hospitalized adults.
- Who are InflaRx's investors?
- InflaRx's investors include Bain Capital Life Sciences, RA Capital.
- How much funding has InflaRx raised?
- InflaRx has disclosed $150M raised across 1 round.
- Where is InflaRx headquartered?
- InflaRx is headquartered in Jena, DE.